Icecure Medical opened lower at $0.74, compared with its previous close of $0.74. In the last trading session, the stock traded between $0.70 and $0.74. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Icecure Medical is now worth
$ 0.37
Resulting in a loss of
$ 99.63 (99.63%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.04 (-5.00%)
Day High
$0.74
Day Low
$0.70
Day Open
$0.74
Prev Close
$0.74
Volume
44,300
1W Return
-10.31%
1M Return
-34.11%
3M Return
-79.71%
6M Return
-90.21%
1Y Return
-96.60%
Market Cap ($ Mn)
2
PE Ratio
-
PB Ratio
0.66
PEG Ratio
-
ROE
-220.46%
ROCE
-218.66%
EPS (TTM)
$-1.25
1 Week
-10.31%
1 Month
-34.11%
3 Months
-79.71%
6 Months
-90.21%
9 Months
-96.02%
IceCure Medical treats first patient in ChoICE breast cancer study
First patient treated at West Cancer Center in Tennessee. ChoICE Study enrolls ~400 patients across 30 US sites. Evaluates ProSense cryoablation for low-risk breast cancer. Sites serve as both study centers and commercial locations.
16 days agoIcecure Medical H1FY26 Results: Revenue up 45% YoY to $1.8 million
Revenue grew 45% YoY to $1.8 million in H1FY26, driven by system and probe sales. Gross margin expanded to 30% from 28%, aided by scale despite FX headwinds. Net loss widened to $8.8 million due to increased R&D and sales investments. U.S. commercial installed base grew 70% to over 30 active sites. Cash position strengthened to $12 million following recent financing activities.
1mo agoIceCure Medical signs exclusive Netherlands distribution deal with Scovas
IceCure Medical signed exclusive distribution deal with Scovas Medical for ProSense systems in Netherlands. Agreement covers breast cancer and interventional oncology markets with initial term structure. Partnership aims to support market development and physician access in region with strong IR expertise. THERMAC trial advances to Phase III citing 94% ablation rate and 0% complication rate.
2mo agoIceCure Medical gets IRB approval for ProSense breast cancer study
IceCure Medical Ltd. secured Institutional Review Board approval from West Cancer Center & Research Institute for its ChoICE Study. The post-marketing study evaluates ProSense cryoablation for low-risk breast cancer in women aged 70 and above. Patient enrollment is scheduled to begin shortly following the regulatory clearance.
2mo agoIcecure Medical Q2 Results: EPS beats estimate, sales miss
Icecure Medical reported a Q2 loss of $(1.37) per share, beating the $(1.40) estimate by 2.14%. Revenue grew 69.33% YoY to $889,000 but missed the $1.45 million consensus by 38.7%.
3mo agoSIO petitions NCCN to include cryoablation in breast cancer guidelines
The Society of Interventional Oncology petitioned the NCCN on July 29, 2026, to include percutaneous cryoablation as a Category 2B treatment option for low-risk breast cancer. The proposal supports IceCure Medical's ProSense system, targeting patients aged 70+ and select patients aged 50-69, aiming to influence clinical adoption and reimbursement.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Icecure Medical is now worth
$ 0.37
Resulting in a loss of
$ 99.63 (99.63%)
Note: Past profits do not guarantee future returns.
